CAS: 130645-48-6; 2-Bromo-4-Methylpyrimidine

相似化合物

16879-39-3 1209459-16-4 171408-73-4

上下游产品

CAS号108-52-1 2-氨基-4-甲基嘧啶 | CAS号13036-57-2 2-氯-4-甲基嘧啶 | CAS号15231-48-8 4-嘧啶-2-酮 | CAS号122918-19-8 2-(6-bromopyrid...

📜2-氨基-4-甲基嘧啶置于氢溴酸,Sodium Bromide,Sodium Nitrite体系中,用 水 用作溶剂,化学反应 4.0H,以23%的收率获得2-溴-4-甲基嘧啶
参考文献:新型杂芳族络合剂及其their(III)和ter(III)螯合物的发光
标题:新型杂芳族络合剂及其their(III)和ter(III)螯合物的发光
摘要:合成了十二种杂芳族络合剂9A-i,目的是为基于时间分辨的发光的生物亲和力分析开发合适的标记.确定了它们的euro(III)和ter(III)螯合物的相对发光产率,激发最大值和发射衰减常数.根据这些结果,2,2',2'',2‴-[(2,2'-联吡啶-6,6'-二基)双(亚甲基腈)]四(乙酸)(9E)和2,2',2″,2'-[(2,2':6',2″-叔吡啶-6,6″-二基)双(亚甲基腈)]四(乙酸)(91)是最有前途的试剂.
Doi:10.1002/hlca.19920750517

专利信息

专利号:US-9879022-B2
优先权日:2014-04-04
标题:Bicyclic-fused heteroaryl or aryl compounds
发明人：TRZUPEK JOHN DAVID; LEE KATHERINE LIN; BUNNAGE MARK EDWARD; HAN SEUNGIL; HEPWORTH DAVID; LOVERING FRANK ELDRIDGE; MATHIAS JOHN PAUL; PAPAIOANNOU NIKOLAOS; PIERCE BETSY SUSAN; STROHBACH JOSEPH WALTER; WRIGHT STEPHEN WAYNE; ZAPF CHRISTOPH WOLFGANG; GAVRIN LORI KRIM; LEE ARTHUR; ANDERSON DAVID RANDOLPH; CURRAN KEVIN JOSEPH; DEHNHARDT CHRISTOPH MARTIN; SAIAH EDDINE; GOLDBERG JOEL ADAM; WANG XIAOLUN; HUANG HORNG-CHIH; VARGAS RICHARD; LOWE MICHAEL DENNIS; PATNY AKSHAY
权利人:PFIZER
摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-6376503-B1
优先权日:1997-06-18
标 题 :Alpha 1a adrenergic receptor antagonists
发明人：PATANE MICHAEL A; BOCK MARK G; NEWTON RANDALL C; LAGU BHARAT
权利人:MERCK & CO INC; SYNAPTIC PHARMA CORP
摘要:This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.